Par Pharmaceutical

I'll research this company before writing the profile.

Let me verify the ownership history and the specific EUSA Pharma case.

Company overview. Par Pharmaceutical, Inc. is the principal U.S. generic-drug operating company of Par Pharmaceutical Holdings, Inc., founded in 1978 and headquartered in Chestnut Ridge, New York (with earlier offices in Woodcliff Lake, NJ and Spring Valley, NY). Par is not separately publicly traded: TPG Capital acquired it in 2012 for about $1.9 billion, and Endo International plc (Dublin HQ; U.S. HQ Malvern, PA) bought it in a deal valued at roughly $8.05 billion that closed September 28, 2015. Par has since operated as an Endo subsidiary (Endo reorganized in Chapter 11 proceedings filed in 2022; confirm current entity status before relying on it). Publicly disclosed size: ~900 employees (2013) and revenue of $1,308.6 million for FY2014.

Products / operations. Par develops, manufactures, markets and distributes generic prescription drugs, concentrated on high-barrier-to-entry products: extended- and immediate-release oral solids, orally disintegrating tablets, capsules, powders, injectables (via Par Sterile Products, formerly JHP Pharmaceuticals), nasal sprays, ophthalmics and transdermal patches. As of December 31, 2014 it reported ~95 marketed products, more than 200 pipeline products, 115 pending ANDAs, and five FDA-approved manufacturing plants (four U.S., one India). A smaller branded arm, Par Specialty Pharmaceuticals (formerly Strativa), markets niche branded products. Par also supplies authorized generics for brand partners.

Patent-litigation posture. Operating company, not an NPE. The tracked record shows one case, as plaintiff, filed 2014-07-09 at the USPTO PTAB — i.e., a generic manufacturer petitioning to cancel a brand company's patent, the standard Hatch-Waxman offensive posture. There are zero defendant-side cases in this dataset and no district-court venue clustering (no Eastern District of Texas entries); note this reflects limited database coverage of Par's many ANDA suits, not an absence of district-court litigation.

Notable cases / context. The single tracked matter is Par Pharmaceutical v. EUSA Pharma (USA), Inc. (PTAB, July 2014). EUSA Pharma (USA) was a Jazz Pharmaceuticals subsidiary following Jazz's 2012 acquisition of EUSA, and held assets such as the imaging agent ProstaScint. The specific patent at issue was not verifiable from available sources. Par was separately an active PTAB petitioner against Jazz's Xyrem patents alongside Amneal, and a frequent ANDA defendant/appellant in disputes with Novartis, Bayer and others.